| P2093 | author name string | Michael J Sailor | |
| | Lingyun Cheng | |
| | William R Freeman | |
| | Feiyan Ma | |
| | Huiyuan Hou | |
| | Kaihui Nan | |
| P2860 | cites work | Evaluation of mammalian cell adhesion on surface-modified porous silicon | Q28240790 |
| | Efficacy of daunorubicin encapsulated in liposome for the treatment of proliferative vitreoretinopathy | Q30967615 |
| | Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres | Q33267927 |
| | Development and evaluation of novel biodegradable microspheres based on poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies | Q33276320 |
| | The effect of lauryl capping group on protein release and degradation of poly(D,L-lactic-co-glycolic acid) particles | Q34349780 |
| | Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles | Q34514512 |
| | Sustained Release of a Monoclonal Antibody from Electrochemically Prepared Mesoporous Silicon Oxide | Q34518061 |
| | Mechanism of drug release from double-walled PDLLA(PLGA) microspheres | Q34604761 |
| | Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system | Q36620642 |
| | Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle | Q37152071 |
| | Porous silicon in drug delivery devices and materials | Q37174934 |
| | Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease | Q37315556 |
| | Development of PLGA-based itraconazole injectable nanospheres for sustained release | Q37340997 |
| | Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles | Q37416468 |
| | Recent advances in porous silicon technology for drug delivery. | Q38123855 |
| | Synthesis of mesoporous silica nanoparticle-encapsulated alginate microparticles for sustained release and targeting therapy. | Q39101325 |
| | Real-time cellular analysis as a novel approach for in vitro cytotoxicity testing of medical device extracts | Q39193910 |
| | Engineering porous silicon nanostructures as tunable carriers for mitoxantrone dihydrochloride. | Q39219185 |
| | Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation | Q39785855 |
| | Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin. | Q41348682 |
| | Controlled release carrier of BSA made by W/O/W emulsion method containing PLGA and hydroxyapatite. | Q42813975 |
| | Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation | Q44300085 |
| | PLGA/mesoporous silica hybrid structure for controlled drug release | Q44985378 |
| | Engineering the chemistry and nanostructure of porous silicon Fabry-Pérot films for loading and release of a steroid. | Q45165948 |
| | Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles | Q46057938 |
| | PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery | Q46181738 |
| | In vitro drug release behavior, mechanism and antimicrobial activity of rifampicin loaded low molecular weight PLGA-PEG-PLGA triblock copolymeric nanospheres. | Q46280577 |
| | Reduction in burst release of PLGA microparticles by incorporation into cubic phase-forming systems. | Q46436459 |
| | Relationship between the solution thermodynamic properties of naproxen in organic solvents and its release profiles from PLGA microspheres. | Q46636977 |
| | Preparation and characterization of melittin-loaded poly (DL-lactic acid) or poly (DL-lactic-co-glycolic acid) microspheres made by the double emulsion method | Q46778879 |
| | Reduction in burst release after coating poly(D,L-lactide-co-glycolide) (PLGA) microparticles with a drug-free PLGA layer | Q52901477 |
| | Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy | Q68038301 |
| | The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy | Q68158791 |
| | Daunomycin in the treatment of experimental proliferative vitreoretinopathy. Effective doses in vitro and in vivo | Q70110899 |
| | Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit | Q70645633 |
| | Proliferative vitreoretinopathy: an overview | Q77144020 |
| | Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group | Q77436658 |
| | A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity | Q85160576 |
| P433 | issue | 8 | |
| P921 | main subject | daunorubicin | Q411659 |
| | microsphere | Q1759020 |
| P304 | page(s) | 3505-3512 | |
| P577 | publication date | 2014-05-02 | |
| P1433 | published in | Acta Biomaterialia | Q4676719 |
| P1476 | title | Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin | |
| P478 | volume | 10 | |